Completed Equality Screenings - Quarter 2 - July 2013 - September 2013
Date published:
In fulfilling the commitments within its Equality Scheme the Department equality screens policies to assess the impact and determine if a full Equality Impact Assessment (EQIA) is required.
Documents
- NICE Clinical Guideline CG155 - Psychosis and schizophrenia in children and young people
- NICE Clinical Guideline CG 159 - Social anxiety disorder
- NICE Clinical Guideline CG160 - Feverish illness in children
- NICE Clinical Guideline CG161 - The assessment and prevention of falls in older people
- NICE Clinical Guideline CG162- Stroke rehabilitation
- NICE Clinical Guideline CG163 - Idiopathic pulmonary fibrosis
- NICE Clinical Guideline CG164 - Familial breast cancer
- NICE Clinical Guideline CG165 - Hepatitis B (chronic): Diagnosis and management of chronic hepatitis B in children, young people and adults
- NICE Clinical Guideline CG166 - Ulcerative colitis: management in adults, children and young people
- NICE Clinical Guideline CG167 - Myocardial Infarction with ST-segment elevation (STEMI)
- NICE Technology Appraisal – TA 283 Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
- NICE Technology Appraisal – TA284 Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
- NICE Technology Appraisal – TA285 Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
- NICE Technology Appraisal – TA287 Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
- NICE Technology Appraisal – TA288 Dapagliflozin in combination therapy for treating type 2 diabetes
- NICE Technology Appraisal TA 289 - Ruxolitinib for disease-related splenomegaly or symptoms in adult with myelofibrosis
- NICE Technology Appraisal TA 290 - Mirabegron for treating symptoms of overactive bladder
- NICE Technology Appraisal TA 291 - Pegloticase for treating severe debilitating chronic tophaceous gout
- NICE Technology Appraisal – TA 292 Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder
- NICE Technology Appraisal - TA293 Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (review of technology appraisal 205)
- NICE Technology Appraisal – TA 294 Aflibercept solution for injection for the first line treatment of wet age-related macular degeneration